HOLD with tightened risk parameters: stop loss at $202 (above 200 SMA), partial trim of 10-15% now, no adds on 50 SMA tests

• Volume distribution: 5.3M shares on Oct 1 selloff versus 3.89M shares on Oct 2 bounce represents textbook distribution pattern, not digestion
• ATR compressed from 7.21 to 5.96 (~17% volatility reduction); volatility compression near key resistance is a coiled risk event with negative bias
• 2022 operating margin of 28.3% included non-recurring Veralto spin-off gains; apples-to-apples historical comparison is ~22%, not 28.3%
• Current operating margin at 19.8% with Q4 2025 EPS $1.68, Q1 2026 EPS $1.45, Q2 2026 EPS $1.23—three consecutive quarters of declining earnings
• Q2 2026 decline attributed to acquisition integration costs; management already signaling the realized one is not the trough
• Aggressive analyst targets $230 (upper Bollinger Band at 2 standard deviations) versus realistic resistance at September 28 swing high $226.93
• 200 SMA support at $200.81 and lower Bollinger Band at $195.77 define actual risk-reward as closer to 1-to-1 with slight negative skew
• Goodwill stands at $47.4B (51% of total assets); integration disappointment could trigger 15-20% drawdown in a single quarter
• DHR committing ~$5.7B new equity capital at 7.6% ROE—below cost of equity—for 2-3 years during integration
• GLP-1 secular tailwind already reflected in forward P/E of 23x; no visible acceleration beyond consensus to justify further re-rating
• Catalyst-free environment means no fundamental reason for stock to re-rate higher or defend against macro shocks, sector rotation, or risk-on rotations
• Partial trim at 50 SMA (25-33% trim recommendation) retains 67-75% of position if 50 SMA holds while de-risking before larger drawdown
• MACD bearish crossover and distribution-style volume together justify de-risking at current levels rather than waiting for 50 SMA confirmation

→ vs aggressive: Volume distribution (5.3M selloff vs 3.89M bounce) is not 'reconsolidation'—supply is overwhelming demand on both legs; framing as 'digestion' is confirmation bias anchored on the prior 13% rally

→ vs aggressive: ATR compression from 7.21 to 5.96 (~17%) is not neutral—volatility compression near resistance with rolling momentum is a coiled spring with negative bias, not a benign setup

→ vs aggressive: 530bps margin expansion is not the base case; normalizing for non-recurring Veralto gains, the true comparison is 22% vs current 19.8%, a much smaller move that has not materialized

→ vs aggressive: Aggressive ROE normalization to 12-15% ignores that DHR is value-destroying for 2-3 years at $5.7B below cost of equity during integration; not conceded

→ vs aggressive: 'No catalysts cuts both ways' is inverted—catalyst-free means no re-rating catalyst AND no defense against macro shocks; absence of news is not a tailwind

→ vs aggressive: 2.5-to-1 risk-reward depends on reaching $230 (upper Bollinger Band), a statistical extreme, not a base case; realistic risk-reward is ~1-to-1 using visible support/resistance levels

→ vs aggressive: Trim-at-50-SMA is not structurally flawed—waiting for confirmed close below 50 SMA means realizing larger losses before acting; partial trim preserves 67-75% upside while de-risking

→ vs aggressive: Adding a half-position on 50 SMA test with no catalyst is adding capital into deteriorating price action, a reliable way to lock in losses

→ vs aggressive: GLP-1 tailwind already priced into 23x forward P/E; priced-in tailwind is not a catalyst for further upside

Maintain HOLD, preserve current position, use 50 SMA break at 208.45 as trim trigger (25-33%), hold $200 stop (just below 200 SMA at 200.81), and wait for post-Q3 earnings or 10 EMA reclaim at 217.81 on expanding volume before considering adds.

• Long-term uptrend intact: price above 200 SMA (200.81) with 50 SMA (208.45) above 200 SMA provides legitimate trend filter
• Volume pattern is a concern: 5.3M shares on down move vs 3.89M on bounce is a real distribution signal that favors the downside
• EPS bridge requires 400-500 bps operating margin expansion from ~19.8% to 24-25%—heroic assumption requiring flawless Cytiva integration
• Forward $9.30 EPS priced at 23x forward provides limited upside cushion if integration takes longer
• Fundamentals remain supportive: $4.3B trailing FCF, 2.77x net debt/EBITDA, 37x interest coverage, 0.81 beta provides defensive floor
• Technical setup is neutral: RSI at 50, Bollinger middle band at 213 being respected, MACD still positive at 3.40, 50 SMA rising
• Q3 earnings is the next major catalyst to resolve current ambiguity between bull and bear cases

→ vs aggressive: Volume distribution day (5.3M down vs 3.89M up) contradicts framing of October pullback as 'healthy digestion'—selective use of 13% prior rally to rationalize 4% pullback is confirmation bias

→ vs aggressive: EPS bridge uses adjusted 2022 peak of ~22% operating margin (not 28% including Veralto gains), so implied expansion from 19.8% to 24-25% requires 400-500 bps jump—not a base case but an outcome requiring flawless integration with no disruption

→ vs conservative: Stop at $202 is 1 dollar above 200 SMA at 200.81, selling just before the most important support level in the chart—if 200 SMA holds, you've sold at a major bottom level; if it breaks, stock likely tests 195 anyway

→ vs conservative: Preemptive 10-15% trim at 50 SMA at 208.45 is over-rotation: MACD still positive at 3.40, 50 SMA not broken, RSI neutral at 50, and reactive trimming turns manageable drawdowns into chronic underperformance

→ vs conservative: Framing DHR as lacking catalyst support misses its defensive compounder characteristics—0.81 beta, dividend, and $4.3B FCF provide sticky institutional bid that holds value in catalyst-free environments